The results showed that in this cohort, patients with COVID-19 presented lower levels of adiponectin compared with controls and that these levels were significantly associated with the occurrence of hyperglycemic-derived adverse severe outcomes during disease progression. This evidence concerns the gene ADIPOQ and COVID-19.